oral semaglutide efficacy Novo Nordisk's Wegovy® pill (oral 25 mg, once daily) has just been approved by the US FDA as the first GLP‑1 receptor agonist for long‑term weight management and CV risk The Importance of Patient-Reported Outcomes

Patients with type 2 diabetes who have established diabetic retinopathy at treatment initiation face the highest risk, particularly when experiencing rapid A1c reductions within the first 16 weeks of therapy

Most events were transient and occurred during dose escalation

Patients are encouraged to stay hydrated, follow dietary recommendations, and ask questions to feel confident before starting their GLP-1 weight loss journey

Origin Story Starts With A Venomous Lizard Exendin-4, a peptide hormone discovered in 1991 in the venom of the Gila monster, was structurally similar to the human hormone glucagon-like peptide-1, explained Joji Suzuki, M.D., FACLP, director of the Division of Addiction Psychiatry at Brigham and Womens Hospital